Date Added: 20/03/2017
Date Updated: 20/03/2017
Avacopan for ANCA-associated vasculitis – first and subsequent line
Specialties: Orthopaedics, rheumatology & podiatry
Technology Type: Drugs
Stage of development: Experimental - pilot or phase II
Stage of EAA: Prioritised for assessment
Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) – first and subsequent line.
Avacopan (CCX-168) is a small molecule, complement C5a receptor inhibitor. Chemoattractant receptors, such as C5aR, are receptors for complement proteins involved in specific inflammatory responses. C5a is believed to be a potent chemoattractant underlying the inflammation-induced damage in certain autoimmune disorders, including AAV, thus inhibitors of C5aR have a therapeutic potential.